To use all functions of this page, please activate cookies in your browser.
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
37 Current newsrss
All further development of TB-402 will be stopped
ThromboGenics NV and co-development partner BioInvent International announced the results from a Phase IIb trial comparing TB-402, a long acting anticoagulant, against rivaroxaban (Xarelto®; Bayer...
Three non-executive directors and two business development managers join to help expand the Company’s growing manufacturing business
Europe AB and a board member of BioInvent International AB, KaroBio AB and Pharmalink AB. Elisabeth has significant senior management experience with Pharmacia Corporation, Octapharma AB and Diamyd Medical...
BioInvent International AB announced that new preclinical data has been presented on its BI-505 programme that demonstrates anti-cancer activity in multiple myeloma and beneficial effect on bone...
. Lindner is a Director at BioInvent International AB and Karo Bio AB, and serves as Director of the Royal Swedish Academy of Engineering Science. She holds an MSc from Stockholm University and an M.B.A from...
Two new studies now ongoing: phase Ib/II in patients with aggressive brain tumour and phase Ib in primary liver cancer
BioInvent International AB and co-development partner ThromboGenics NV announced that their partner Roche has dosed the first patient in a phase Ib/II study with the novel antibody anti-cancer agent...
Trial to assess the benefits of partial Factor VIII inhibition in total hip replacement surgery patients
ThromboGenics NV and co-development partner BioInvent International announce that the first patient has been dosed in a Phase IIb trial with their novel long-acting anticoagulant TB-402 (Anti...
Trial start triggers US$ 15 million milestone from Genentech
BioInvent International AB announced the dosing of the first patient in the phase II study of the Company’s antibody, BI-204. The product candidate is being developed for secondary prevention...
ThromboGenics NV and co-development partner BioInvent International announce today that the positive TB-402 (Anti-Factor VIII) Phase II trial results, evaluating the product’s efficacy and safety...
Lead candidate for inflammation to progress into preclinical development
BioInvent International AB announced that it has signed an agreement to extend its existing collaboration with an undisclosed Japanese pharmaceutical group. The extended collaboration comes...
BioInvent International AB announced IND clearance from the U.S. Food & Drug Administration (FDA) to initiate a Phase II study for BI-204. BI-204 is a human monoclonal antibody that specifically...